SAN FRANCISCO, CA--(Marketwired - December 15, 2016) - Cantabio Pharmaceuticals, Inc. (OTCQB: CTBO), a biopharmaceutical company developing novel disease modifying therapies for Alzheimer's, Parkinson's and other related neurodegenerative diseases today announced that the company has been selected to present at the 9th Annual Biotech Showcase on January 10th, 2017. The company's CEO, Dr Gergely Tóth, will give a presentation at 3pm in San Francisco at the Hilton San Francisco Union Square in Room 8 (Ballroom Level).
The company will present an update on its operations, activities and research progress, and will also be attending the Annual JP Morgan Conference week in San Francisco during January 9-12, 2017, meeting with potential large pharmaceutical company partners and investors.
About Cantabio Pharmaceuticals, Inc.
Cantabio is focused on bringing novel, first-in-class drug candidates into clinical trials and beyond through the discovery and development of innovative pharmacological chaperone and protein delivery based therapeutics, focusing on protein systems implicated in neurodegenerative disorders, including Alzheimer's and Parkinson's, and oxidative stress. The company is currently engaged in advanced pre-clinical trials of its therapeutic candidates and is focused on developing these towards clinical trials. More information is available at www.cantabio.com.
About the 9th Annual Biotech Showcase
The Annual Biotech Showcase is San Francisco's exclusive investor and networking event, where innovation meets investors during biotech's most impactful event of the year. https://ebdgroup.knect365.com/biotech-showcase
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.